However, these patients inevitably develop resistance to EGFR-TKIs after a median time of approximately 6 to 8 months.[1,2] Numerous resistance mechanisms have been discovered to date;[3] notably, the EGFR T790M mutation,[4] MET amplification,[5] and histologic transformation including small cell lung cancer (SCLC) transformation[6] have all been suggested as common possible mechanisms of TKI resistance. This evidence concerns the gene EGFR and small cell lung carcinoma.